BioDrugs

, Volume 27, Issue 2, pp 85–95 | Cite as

B-Cell Targeted Therapies in Systemic Lupus Erythematosus

Successes and Challenges
Leading Article

Abstract

Systemic lupus erythematosus is a multisystem autoimmune disease characterized by the formation of autoantibodies that target a variety of self antigens. B cells are fundamental to the development of these antibodies and are a target for intervention in the disease. This review discusses four therapies that target B cells by inducing B-cell depletion, reduction in B-cell proliferation and differentiation, or modulation of B-cell function. Rituximab is an anti-CD20 chimeric monoclonal antibody that depletes B cells but not plasma cells. Systematic reviews of open label studies, particularly in lupus patients refractory to conventional therapy, have suggested that rituximab can be an effective treatment for non-renal lupus and lupus nephritis. However, randomized, double-blind, controlled trials comparing rituximab with placebo in addition to standard of care therapy for non-renal lupus and lupus nephritis over 12 months failed to demonstrate efficacy using the planned primary endpoints, although there were some post-hoc analyses suggesting that rituximab may have beneficial effects that would be worthy of further study as no significant toxicity has been demonstrated. Treatment with belimumab, a humanized monoclonal antibody targeted against B lymphocyte stimulator (BLys), was more efficacious than placebo and had no significant increase in adverse events in two non-renal, phase III lupus trials when given in addition to standard of care therapy for 52 weeks. Belimumab is licensed for the management of lupus in the US and in Europe. Atacicept is a humanized fusion protein that binds BLys and APRIL (a proliferation-inducing ligand) that might be more effective than belimumab in the management of lupus. Unfortunately a phase II/III trial of atacicept in lupus nephritis had to be stopped due to the development of low immunoglobulin levels and pneumonias in some patients. However, in retrospect these complications may have been due to concomitant treatment with mycophenolate mofetil and results of a 52-week, non-renal, phase III trial with atacicept are awaited. Epratuzumab is a humanized monoclonal antibody that targets CD22 on B cells and results in modulation of B-cell function and migration, as CD22 regulates adhesion and inhibits B-cell receptor (BCR) signalling. Epratuzumab at a cumulative dose of 2,400 mg over 4 weeks has been shown to improve lupus disease activity compared with placebo 12 weeks after initiation of therapy in a phase II study, and a 12-month phase III study is on-going. B-cell targeted therapies are an attractive prospect for treating lupus disease and the results of current phase III trials are eagerly awaited. Finding the most appropriate trial design to demonstrate efficacy in lupus trials has been a challenge. The SRI (SLE response index) used in the belimumab studies and the BICLA (British Isles Lupus Assessment Group-based Composite Lupus Assessment) used in the epratuzumab studies are currently the promising trial designs for non-renal studies. For lupus nephritis it is important that trials are of adequate duration to be able to demonstrate benefit of new therapies over conventional therapy.

References

  1. 1.
    Lund FE. Cytokine-producing B lymphocytes: key regulators of immunity. Curr Opin Immunol 2008; 20:332–8.Google Scholar
  2. 2.
    Yurasov S, Tiller T, Tsuiji M, et al. Persistent expression of autoantibodies in SLE patients in remission. J Exp Med. 2006;203:2255–61.PubMedCrossRefGoogle Scholar
  3. 3.
    Amissah-Arthur MB, Gordon C. Contemporary treatment of systemic lupus erythematosus: an update for clinicians. Ther Adv Chronic Dis. 2010;1:163–75.PubMedCrossRefGoogle Scholar
  4. 4.
    Gayed M, Gordon C. Novel treatments for systemic lupus erythematosus. Curr Opin Investig Drugs. 2010;11:1256–64.PubMedGoogle Scholar
  5. 5.
    Isenberg D, Gordon C, Merrill J, et al. New therapies in systemic lupus erythematosus: trials, troubles and tribulations…. working towards a solution. Lupus. 2008;17:967–70.PubMedCrossRefGoogle Scholar
  6. 6.
    Bruce IN, Gordon C, Merrill JT, et al. Clinical trials in lupus: what have we learned so far? Understanding the gap between reality and expectation. Rheumatology. 2010;49:1025–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Gordon C, Bertsias G, Ioannidis JP, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. Ann Rheum Dis. 2009;68:470–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Bertsias GK, Ioannidis JP, Boletis J, et al. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints. Ann Rheum Dis. 2009;68:477–83.PubMedCrossRefGoogle Scholar
  9. 9.
    Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 2012;64:3660–5.PubMedCrossRefGoogle Scholar
  10. 10.
    Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:3077–87.PubMedCrossRefGoogle Scholar
  11. 11.
    Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant. 2006;6:859–66.PubMedCrossRefGoogle Scholar
  12. 12.
    Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010;62:222–33.PubMedCrossRefGoogle Scholar
  13. 13.
    Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64:1215–26.PubMedCrossRefGoogle Scholar
  14. 14.
    Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus. 2009;18:767–76.PubMedCrossRefGoogle Scholar
  15. 15.
    Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86:447–58.PubMedGoogle Scholar
  16. 16.
    Isenberg DA, Gordon C; BILAG Group. British Isles Lupus Assessment Group. From BILAG to BLIPS: disease activity assessment in lupus past, present and future. Lupus. 2000; 9:651–4.Google Scholar
  17. 17.
    Appel GB, Contreras G, Dooley MA; Aspreva Lupus Management Study Group, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103–12.Google Scholar
  18. 18.
    Dooley MA, Jayne D, Ginzler EM; ALMS Group, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365:1886–95.Google Scholar
  19. 19.
    Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71:1771–82.PubMedCrossRefGoogle Scholar
  20. 20.
    Gourley MF, Austin HA 3rd, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med. 1996;125:549–57.PubMedCrossRefGoogle Scholar
  21. 21.
    Cortés-Hernández J, Ordi-Ros J, Labrador M, et al. Predictors of poor renal outcome in patients with lupus nephritis treated with combined pulses of cyclophosphamide and methylprednisolone. Lupus. 2003;12:287–96.PubMedCrossRefGoogle Scholar
  22. 22.
    Austin HA 3rd, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Houssiau FA, D’Cruz D, Sangle S; MAINTAIN Nephritis Trial Group. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69:2083–9.Google Scholar
  24. 24.
    Weidenbusch M, Rommele C, Schrottle A, et al. Beyond the LUNAR trial: efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013;28:106–11.PubMedCrossRefGoogle Scholar
  25. 25.
    Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res. 2012;64:797–808.CrossRefGoogle Scholar
  26. 26.
    Merrill J, Buyon J, Furie R, et al. Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER). Lupus. 2011;20:709–16.PubMedCrossRefGoogle Scholar
  27. 27.
    Arkema EV, van Vollenhoven RF, Askling J. Incidence of progressive multifocal leukoencephalopathy in patients with rheumatoid arthritis: a national population-based study. Ann Rheum Dis. 2012;71:1865–7.PubMedCrossRefGoogle Scholar
  28. 28.
    Bharat A, Xie F, Baddley JW, et al. Incidence and risk factors for progressive multifocal leukoencephalopathy among patients with selected rheumatic diseases. Arthritis Care Res. 2012;64:612–5.CrossRefGoogle Scholar
  29. 29.
    Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 2008;67(Suppl. 3):iii64–iii65.Google Scholar
  30. 30.
    Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 2012;64:3043–51.PubMedCrossRefGoogle Scholar
  31. 31.
    Palazzo E, Yahia SA. Progressive multifocal leukoencephalopathy in autoimmune diseases. Jt Bone Spine. 2012;79:351–5.CrossRefGoogle Scholar
  32. 32.
    NHS. NICE publishes draft guidance on belimumab for systemic lupus erythematosus. http://www.nice.org.uk/newsroom/pressreleases/SystemicLupusBelimumabFAD.jsp. Accessed 2012 Aug 5.
  33. 33.
    Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260–3.PubMedCrossRefGoogle Scholar
  34. 34.
    Zhang J, Roschke V, Baker KP, et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol. 2001;166:6–10.PubMedGoogle Scholar
  35. 35.
    Navarra SV, Guzman RM, Gallacher AE; for the BLISS-52 Study Group, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721–31.Google Scholar
  36. 36.
    Furie R, Petri M, Zamani O; for the BLISS-76 Study Group, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918–30.Google Scholar
  37. 37.
    Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61:1143–51.PubMedCrossRefGoogle Scholar
  38. 38.
    Gladman DD, Urowitz MB, Kagal A, et al. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol. 2000;27:377–9.PubMedGoogle Scholar
  39. 39.
    ACR Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity. Arthritis Rheum. 2004;50:3418–26.CrossRefGoogle Scholar
  40. 40.
    Manzi S, Sánchez-Guerrero J, Merrill JT; on behalf of the BLISS-52 and BLISS-76 Study Groups, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71:1833–8.Google Scholar
  41. 41.
    van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71:1343–9.PubMedCrossRefGoogle Scholar
  42. 42.
    EMA. Summary of the European public assessment report (EPAR) for Benlysta. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002015/human_med_001466.jsp&mid=WC0b01ac058001d124. Accessed 2012 Jun 5.
  43. 43.
    Dall’Era M, Chakravarty E, Wallace D; Merck Serono and ZymoGenetics Atacicept Study Group, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus, results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007;56:4142–50.Google Scholar
  44. 44.
    Huard B, Tran NL, Benkhoucha M, et al. Selective APRIL blockade delays systemic lupus erythematosus in mouse. PLoS One. 2012;7(2):e31837.PubMedCrossRefGoogle Scholar
  45. 45.
    Koyama T, Tsukamoto H, Miyagi Y, et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis. 2005;64:1065–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Ginzler EM, Wax S, Rajeswaran A, et al. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther. 2012;14:R33.PubMedCrossRefGoogle Scholar
  47. 47.
    Otipoby KL, Andersson KB, Draves KE, et al. CD22 regulates thymus independent responses and the lifespan of B cells. Nature. 1996;384:634–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Tsai DE, Schuster SJ, Matthies A, et al. Progressive intermediate-grade non-Hodgkin’s lymphoma after high-dose therapy and autologous peripheral stem-cell transplantation: changing the natural history with monoclonal antibody therapy. Clin Lymphoma. 2000;1:62–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Daridon C, Blassfeld D, Reiter K, et al. Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. Arthritis Res Ther. 2010;12:R204.PubMedCrossRefGoogle Scholar
  50. 50.
    Dorner T, Kaufmann J, Wegener WA, et al. Initial clinical trial of epratuzumab (humanized anti-cd22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther. 2006;8:R74.PubMedCrossRefGoogle Scholar
  51. 51.
    Petri M, Hobbs K, Gordon C, et al. Randomized controlled trials of epratuzumab (anti CD-22 mab targeting B cells) reveal clinically meaningful improvements in patients with moderate/severe SLE flares. Ann Rheum Dis. 2008;67(Suppl. II):53.Google Scholar
  52. 52.
    Wallace D, Hobbs K, Houssiau F, et al. Randomized controlled trials of epratuzumab (anti-CD22 MAB targeting B-cells) reveal clinically meaningful reductions in corticosteroid use with favorable safety profile in moderate and severe flaring SLE patients. Ann Rheum Dis. 2008;67(Suppl. II):212.Google Scholar
  53. 53.
    Wallace DJ, Kalunian KC, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2013;. doi:10.1136/annrheumdis-2012-202760.Google Scholar
  54. 54.
    Petri M, Pike MC, Kelley L, et al. Systemic lupus erythematosus responder index assessment of responders in EMBLEM, a phase IIb study in patients with moderate to severe systemic lupus erythematosus. Arthritis Rheum. 2011;64(10, Suppl.):1378.Google Scholar
  55. 55.
    Furie R, Nicholls K, Cheng T-T, et al. Efficacy and safety of abatacept over 12 months in patients with lupus nephritis: results from a multicenter, randomized, double-blind, placebo-controlled phase II/III study. Arthritis Rheum. 2011;63:S962–3.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.Department of RheumatologySandwell and West Birmingham Hospitals, NHS TrustBirminghamUK
  2. 2.Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, The Medical SchoolUniversity of BirminghamBirminghamUK

Personalised recommendations